Download PDF
Thromb Haemost
DOI: 10.1055/a-2706-9879
Cellular Haemostasis and Platelets

Potent Inhibition of Arterial Thrombosis and Venous Thrombogenesis Subject to Adequate Hemostasis via Disrupting β3/Src Interaction in Platelets

Authors

  • Jiayi Chen‡   ‡

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Shuang Liu‡   ‡

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Yan Shen‡   ‡

    2   Research Center for Experimental Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Huan Xiong‡   ‡

    3   Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangdong, China

  • Chao Chen

    4   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  • Bing Xiao

    5   Institute for Development and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Yun Wang

    6   National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

  • Lu Jin

    3   Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangdong, China

  • Wanlin Yu

    7   School of Pharmaceutical Sciences, Southern Medical University, Guangdong, China

  • Dounan Xu

    3   Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangdong, China

  • Zheng Ruan

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Jingqiu Liu

    4   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  • Yaxi Yang

    4   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  • Lianghe Mei

    8   Suzhou Institute of Materia Medica, Suzhou, Jiangsu, China

  • Li Hua

    9   School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Cheng Luo

    3   Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Guangdong, China
    4   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  • Bing Zhou   ‡‡

    4   State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

  • Kankan Wang   ‡‡

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Xiaodong Xi   ‡‡

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Jianhua Mao    ‡‡

    1   Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Collaborative Innovation Center of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Funding Information This study was supported by research funding from the National Natural Science Foundation of China (82370134 and 81970112 to X.X., 82350710226 and 82370178 to K.W., and 82304301 to H.X.), Science and Technology Commission of Shanghai Municipality (23S11900400 and 23ZR1439900 to J.M.), and National Key R&D Program of China (2023YFA1800401 to K.W.).
Further Information
   Permissions and Reprints


Graphical Abstract

Preview

Abstract

Background

Antiplatelet and anticoagulation are the cornerstones for arterial and venous thrombosis, respectively; however, hemorrhage remains a significant clinical challenge. Platelets are crucial for arterial thrombosis and contribute to venous thrombosis. Integrin β3 mediates outside-in signaling, which is critical for thrombosis, while inside-out signaling maintains hemostasis. Targeting the β3/Src interactions to selectively inhibit outside-in signaling offers a promising antithrombotic strategy without compromising hemostasis.

Objectives

To develop more potent small molecules that selectively disrupt the β3/Src interaction, thereby inhibiting arterial and venous thrombogenesis without increasing bleeding risk.

Methods

Building on the previously identified compound DCDBS84, we developed the structurally modified small molecules C109 and C116, with enhanced affinity for the Src SH3 domain. Their antithrombotic effects on both arterial and venous thrombosis were systematically evaluated through in vitro and in vivo studies. The impact on hemostatic function was assessed using a tail-bleeding model. Additionally, the drug developability of C109 was assessed via pharmacokinetic (PK) and metabolite analysis.

Results

C109 and C116 exhibited superior efficacy in disrupting the β3/Src interaction. In vitro and in vivo studies demonstrated that C109 and C116 effectively suppress thrombosis at levels comparable to high doses of the αIIbβ3 antagonist integrilin, without elevating bleeding risk. In the Stenosis Model, C109 and C116 significantly reduced venous thrombogenesis by suppressing platelet activation and neutrophil extracellular trap formation. Additionally, C109 displayed favorable PK properties and robust metabolic stability.

Conclusion

These findings identify promising small molecules that inhibit thrombosis while maintaining hemostasis, providing new avenues for safer and more effective clinical management.

Keywords

antiplatelet agent - hemorrhage - thrombosis - venous thrombosis

‡ These authors contributed equally to this article.


‡‡ These authors share co-corresponding authorship.


Supplementary Material



Publication History

Received: 06 April 2025

Accepted: 18 September 2025

Article published online:
10 October 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403 (10440): 2133-2161
    Search in Google Scholar
  • 2 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12 (10) 1580-1590
    Search in Google Scholar
  • 3 Delluc A, Lacut K, Rodger MA. Arterial and venous thrombosis: what's the link? A narrative review. Thromb Res 2020; 191: 97-102
    Search in Google Scholar
  • 4 Wei K, Huang H, Liu M, Shi D, Ma X. Platelet-derived exosomes and atherothrombosis. Front Cardiovasc Med 2022; 9: 886132
    Search in Google Scholar
  • 5 Liu W, Pircher J, Schuermans A. et al. Jak2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood 2024; 143 (15) 1539-1550
    Search in Google Scholar
  • 6 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13 (01) 34-45
    Search in Google Scholar
  • 7 Potere N, Abbate A, Kanthi Y. et al. Inflammasome signaling, thromboinflammation, and venous thromboembolism. JACC Basic Transl Sci 2023; 8 (09) 1245-1261
    Search in Google Scholar
  • 8 Zhang Z, Zhou X, Zhou X, Cheng Z, Hu Y. Role of platelets and their interaction with immune cells in venous thromboembolism. Semin Thromb Hemost 2024
    Search in Google Scholar
  • 9 Swan D, Turner R, Franchini M, Mannucci PM, Thachil J. Air pollution and venous thromboembolism: current knowledge and future perspectives. Lancet Haematol 2025; 12 (01) e68-e82
    Search in Google Scholar
  • 10 Rosell A, Gautam G, Wannberg F. et al. Neutrophil extracellular trap formation is an independent risk factor for occult cancer in patients presenting with venous thromboembolism. J Thromb Haemost 2023; 21 (11) 3166-3174
    Search in Google Scholar
  • 11 Fuchs TA, Brill A, Duerschmied D. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010; 107 (36) 15880-15885
    Search in Google Scholar
  • 12 Bressan A, Faggin E, Donato M. et al. NETosis in acute thrombotic disorders. Semin Thromb Hemost 2023; 49 (07) 709-715
    Search in Google Scholar
  • 13 Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Association between particulate air pollution and venous thromboembolism: a systematic literature review. Eur J Intern Med 2016; 27: 10-13
    Search in Google Scholar
  • 14 Zhou J, Xu E, Shao K. et al. Circulating platelet-neutrophil aggregates as risk factor for deep venous thrombosis. Clin Chem Lab Med 2019; 57 (05) 707-715
    Search in Google Scholar
  • 15 Burkard P, Schonhart C, Vögtle T. et al. A key role for platelet GPVI in neutrophil recruitment, migration, and NETosis in the early stages of acute lung injury. Blood 2023; 142 (17) 1463-1477
    Search in Google Scholar
  • 16 Yago T, Liu Z, Ahamed J, McEver RP. Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice. Blood 2018; 132 (13) 1426-1437
    Search in Google Scholar
  • 17 van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol 2019; 16 (03) 166-179
    Search in Google Scholar
  • 18 Halvorsen S, Andreotti F, ten Berg JM. et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014; 64 (03) 319-327
    Search in Google Scholar
  • 19 McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol 2018; 15 (03) 181-191
    Search in Google Scholar
  • 20 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    Search in Google Scholar
  • 21 Becattini C, Agnelli G, Schenone A. et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366 (21) 1959-1967
    Search in Google Scholar
  • 22 Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Rev 2020; 39: 100619
    Search in Google Scholar
  • 23 Chen J, Liu S, Ruan Z, Wang K, Xi X, Mao J. Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk. Blood Rev 2024; 67: 101220
    Search in Google Scholar
  • 24 Zhou X, Wu X, Sun H, Li J. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: a systematic review and meta-analysis. J Evid Based Med 2017; 10 (02) 136-144
    Search in Google Scholar
  • 25 Huang J, Li X, Shi X. et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol 2019; 12 (01) 26
    Search in Google Scholar
  • 26 Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. Physiology (Bethesda) 2017; 32 (02) 162-177
    Search in Google Scholar
  • 27 Arias-Salgado EG, Lizano S, Shattil SJ, Ginsberg MH. Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain. J Biol Chem 2005; 280 (33) 29699-29707
    Search in Google Scholar
  • 28 Katyal P, Puthenveetil R, Vinogradova O. Structural insights into the recognition of β3 integrin cytoplasmic tail by the SH3 domain of Src kinase. Protein Sci 2013; 22 (10) 1358-1365
    Search in Google Scholar
  • 29 Wu Y, Span LM, Nygren P. et al. The tyrosine kinase c-Src specifically binds to the active integrin αIIbβ3 to initiate outside-in signaling in platelets. J Biol Chem 2015; 290 (25) 15825-15834
    Search in Google Scholar
  • 30 Mao J, Zhu K, Long Z. et al. Targeting the RT loop of Src SH3 in platelets prevents thrombosis without compromising hemostasis. Adv Sci (Weinh) 2022; 9 (07) e2103228
    Search in Google Scholar
  • 31 Su X, Mi J, Yan J. et al. RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 2008; 112 (03) 592-602
    Search in Google Scholar
  • 32 Wang Y, Mao J, Li L. et al. Characteristics of the thrombus formation in transgenic mice with platelet-targeted factor VIII expression. Thromb Haemost 2022; 122 (05) 755-766
    Search in Google Scholar
  • 33 Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S A 2003; 100 (23) 13298-13302
    Search in Google Scholar
  • 34 Phillips DR, Prasad KS, Manganello J, Bao M, Nannizzi-Alaimo L. Integrin tyrosine phosphorylation in platelet signaling. Curr Opin Cell Biol 2001; 13 (05) 546-554
    Search in Google Scholar
  • 35 Huang J, Shi X, Xi W, Liu P, Long Z, Xi X. Evaluation of targeting c-Src by the RGT-containing peptide as a novel antithrombotic strategy. J Hematol Oncol 2015; 8: 62
    Search in Google Scholar
  • 36 Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999; 401 (6755) 808-811
    Search in Google Scholar
  • 37 O'Gara PT, Kushner FG, Ascheim DD. et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 127 (04) e362-e425
    Search in Google Scholar
  • 38 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 2016; 134 (10) e123-e155
    Search in Google Scholar
  • 39 Angiolillo DJ, Galli M, Collet JP, Kastrati A, O'Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022; 17 (17) e1371-e1396
    Search in Google Scholar
  • 40 Shen B, Zhao X, O'Brien KA. et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 2013; 503 (7474) 131-135
    Search in Google Scholar
  • 41 Diaz JA, Saha P, Cooley B. et al. Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application. J Thromb Haemost 2019; 17 (04) 699-707
    Search in Google Scholar
  • 42 Yan Y, Yang H, Hu X. et al. Kindlin-3 in platelets and myeloid cells differentially regulates deep vein thrombosis in mice. Aging (Albany NY) 2019; 11 (17) 6951-6959
    Search in Google Scholar
  • 43 Li L, Xu X, Lv K. et al. Asebogenin suppresses thrombus formation via inhibition of Syk phosphorylation. Br J Pharmacol 2023; 180 (03) 287-307
    Search in Google Scholar
  • 44 Thalji NK, Ivanciu L, Davidson R, Gimotty PA, Krishnaswamy S, Camire RM. A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med 2016; 22 (08) 924-932
    Search in Google Scholar
  • 45 Kral-Pointner JB, Haider P, Szabo PL. et al. Reduced monocyte and neutrophil infiltration and activation by P-selectin/CD62P inhibition enhances thrombus resolution in mice. Arterioscler Thromb Vasc Biol 2024; 44 (04) 954-968
    Search in Google Scholar
  • 46 Mandel J, Casari M, Stepanyan M, Martyanov A, Deppermann C. Beyond hemostasis: platelet innate immune interactions and thromboinflammation. Int J Mol Sci 2022; 23 (07) 23
    Search in Google Scholar
  • 47 Gaziano JM, Brotons C, Coppolecchia R. et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046
    Search in Google Scholar
  • 48 Chan FKL, Kyaw MH, Hsiang JC. et al. Risk of postpolypectomy bleeding with uninterrupted clopidogrel therapy in an industry-independent, double-blind, randomized trial. Gastroenterology 2019; 156 (04) 918-925.e1
    Search in Google Scholar
  • 49 Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: implications for new therapeutic strategies. Res Pract Thromb Haemost 2018; 2 (02) 188-198
    Search in Google Scholar
  • 50 Mauri L, Kereiakes DJ, Yeh RW. et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371 (23) 2155-2166
    Search in Google Scholar
  • 51 Qiu Z, Li F, Sang H. et al; RESCUE BT Trial Investigators. Effect of Intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: the RESCUE BT randomized clinical trial. JAMA 2022; 328 (06) 543-553
    Search in Google Scholar
  • 52 Duffett L. Deep venous thrombosis. Ann Intern Med 2022; 175 (09) ITC129-ITC144
    Search in Google Scholar
  • 53 Cannegieter SC, van Hylckama Vlieg A. Venous thrombosis: understanding the paradoxes of recurrence. J Thromb Haemost 2013; 11 (Suppl. 01) 161-169
    Search in Google Scholar
  • 54 Lijfering WM, Timp JF, Cannegieter SC. Predicting the risk of recurrent venous thrombosis: what the future might bring. J Thromb Haemost 2019; 17 (09) 1522-1526
    Search in Google Scholar
  • 55 Zhang M, Hu T, Ma T, Huang W, Wang Y. Epigenetics and environmental health. Front Med 2024; 18 (04) 571-596
    Search in Google Scholar
  • 56 Brighton TA, Eikelboom JW, Mann K. et al; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367 (21) 1979-1987
    Search in Google Scholar
  • 57 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet 2000; 355 (9212) 1295-1302
    Search in Google Scholar
  • 58 Anderson DR, Dunbar M, Murnaghan J. et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018; 378 (08) 699-707
    Search in Google Scholar
  • 59 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160 (06) e545-e608
    Search in Google Scholar
  • 60 Weitz JI, Lensing AWA, Prins MH. et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    Search in Google Scholar
  • 61 Sidhu VS, Kelly TL, Pratt N. et al; CRISTAL Study Group. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL randomized trial. JAMA 2022; 328 (08) 719-727
    Search in Google Scholar
  • 62 Adair BD, Field CO, Alonso JL. et al. Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model. Nat Commun 2024; 15 (01) 8612
    Search in Google Scholar
  • 63 Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123 (18) 2768-2776
    Search in Google Scholar
  • 64 Thakur M, Junho CVC, Bernhard SM, Schindewolf M, Noels H, Döring Y. NETs-induced thrombosis impacts on cardiovascular and chronic kidney disease. Circ Res 2023; 132 (08) 933-949
    Search in Google Scholar
  • 65 Gianesini S, De Luca L, Feodor T, Taha W, Bozkurt K, Lurie F. Cardiovascular insights for the appropriate management of chronic venous disease: a narrative review of implications for the use of venoactive drugs. Adv Ther 2023; 40 (12) 5137-5154
    Search in Google Scholar
  • 66 Pang A, Cheng N, Cui Y. et al. High-loading Gα13-binding EXE peptide nanoparticles prevent thrombosis and protect mice from cardiac ischemia/reperfusion injury. Sci Transl Med 2020; 12 (552) eaaz7287
    Search in Google Scholar
  • 67 Shen C, Liu M, Xu R. et al. The 14-3-3ζ-c-Src-integrin-β3 complex is vital for platelet activation. Blood 2020; 136 (08) 974-988
    Search in Google Scholar